Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03031730 · OUTCOME

Assess KRT-232 (AMG 232) Exposure-response Relationships (PD, Toxicity, and Efficacy).

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma · Source last updated 2026-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
30 days after last dose

Analysis population: Data were not collected due to study termination prior to participants' assessment at the pre-specified time points.

Groups in this outcome

Part A: Dose Level 1

KRT-232 60 mg + KRd

Part A: Dose Level 2

KRT-232 90 mg + KRd

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A: Dose Level 10
Part A: Dose Level 20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    KRT-232 60 mg + KRd
    id
    OG000
    title
    Part A: Dose Level 1
  2. description
    KRT-232 90 mg + KRd
    id
    OG001
    title
    Part A: Dose Level 2
population Description
Data were not collected due to study termination prior to participants' assessment at the pre-specified time points.
reporting Status
POSTED
time Frame
30 days after last dose
title
Assess KRT-232 (AMG 232) Exposure-response Relationships (PD, Toxicity, and Efficacy).
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice